A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection

Vaccine

Volumn 31, Issue 18, 2013, Pages 2281-2288

  Bragstad, Karoline ^a   Vinner, Lasse ^a,d   Hansen, Mette Sif ^b   Nielsen, Jens ^b   Fomsgaard, Anders ^a,c  

^a STATENS SERUM INSTITUT   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Crossprotection; DNA vaccine; Immunogenicity; Influenza; Pandemic; Pig

Indexed keywords

DNA VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; MATRIX PROTEIN; VIRUS NUCLEOPROTEIN; VIRUS SIALIDASE;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ELECTROPORATION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLUENZA A (H3N2); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; SPANISH INFLUENZA; SWINE; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE MODELS, ANIMAL; IMMUNITY, HETEROLOGOUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; SUS SCROFA; SWINE; SWINE DISEASES; VACCINES, DNA;

EID: 84875854182     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.061     Document Type: Article

References (50)

1. Cheng V.C., To K.K., Tse H., Hung I.F., Yuen K.Y. Two years after pandemic influenza A/2009/H1N1: what have we learned?. Clin Microbiol Rev 2012, 25(2):223-263.
2. Alam S., Sant A.J. Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J Virol 2011, 85(24):13310-13321.
3. Fang Y., Banner D., Kelvin A.A., Huang S.S., Paige C.J., Corfe S.A., et al. Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism. J Virol 2011, 86(4):2229-2238.
4. Skountzou I., Koutsonanos D.G., Kim J.H., Powers R., Satyabhama L., Masseoud F., et al. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J Immunol 2010, 185(3):1642-1649.
5. Weinfurter JT, Brunner K, Capuano 3rd SV, Li C, Broman KW, Kawaoka Y, et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 2011;7(11):e1002381.
6. Coban C., Koyama S., Takeshita F., Akira S., Ishii K.J. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin 2008, 4(6):453-456.
7. Manders P., Thomas R. Immunology of DNA vaccines: CpG motifs and antigen presentation. InflammRes 2000, 49(5):199-205.
8. Pillet S., Kobasa D., Meunier I., Gray M., Laddy D., Weiner D.B., et al. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine 2011, 29(39):6793-6801.
9. Liu M.A., Wahren B., Karlsson Hedestam G.B. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006, 17(11):1051-1061.
10. Ault A., Zajac A.M., Kong W.P., Gorres J.P., Royals M., Wei C.J., et al. Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine 2012, 30(26):3965-3974.
11. Saade F., Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012, 11(2):189-209.
12. Gorres J.P., Lager K.M., Kong W.P., Royals M., Todd J.P., Vincent A.L., et al. DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs. Clin Vaccine Immunol 2011, 18(11):1987-1995.
13. Coban C., Kobiyama K., Aoshi T., Takeshita F., Horii T., Akira S., et al. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 2011, 11(6):479-484.
14. Sardesai N.Y., Weiner D.B. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011, 23(3):421-429.
15. Lin F., Shen X., McCoy J.R., Mendoza J.M., Yan J., Kemmerrer S.V., et al. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 2011, 29(39):6771-6780.
16. Hutnick N.A., Myles D.J., Ferraro B., Lucke C., Lin F., Yan J., et al. Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum Gene Ther 2012, 23(9):943-950.
17. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 2008, 9(10):776-788.
18. Lu S., Wang S., Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008, 7(2):175-191.
19. Drape R.J., Macklin M.D., Barr L.J., Jones S., Haynes J.R., Dean H.J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006, 24(21):4475-4481.
20. Jones S., Evans K., McElwaine-Johnn H., Sharpe M., Oxford J., Lambkin-Williams R., et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009, 27(18):2506-2512.
21. Ledgerwood J.E., Wei C.J., Hu Z., Gordon I.J., Enama M.E., Hendel C.S., et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011, 11(12):916-924.
22. Bragstad K., Martel C.J., Thomsen J.S., Jensen K.L., Nielsen L.P., Aasted B., et al. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades. Influenza Other Respir Viruses 2011, 5(1):13-23.
23. WHO Recommendations for Influenza Vaccine Composition. http://www.who.int/influenza/vaccines/vaccinerecommendations1/en/index3.html.
24. Stanekova Z., Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010, 7:351.
25. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011;162(1-2):19-30.
26. Epstein SL, Kong Wp, Misplon JA, Lo CY, Tumpey TM, Xu L, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005;23(46-47):5404-10.
27. Colman P.M., Ward C.W. Structure and diversity of influenza virus neuraminidase. Curr Top Microbiol Immunol 1985, 114:177-255.
28. Kilbourne E.D., Johansson B.E., Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci USA 1990, 87(2):786-790.
29. Wei C.J., Boyington J.C., McTamney P.M., Kong W.P., Pearce M.B., Xu L., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329(5995):1060-1064.
30. Yewdell J.W., Bennink J.R., Smith G.L., Influenza Moss B A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985, 82(6):1785-1789.
31. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper L, Subbarao K, et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice Emerg Infect Dis 2002;8(8):796-801.
32. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102):1745-1749.
33. Dunham E.J., Dugan V.G., Kaser E.K., Perkins S.E., Brown I.H., Holmes E.C., et al. Different evolutionary trajectories of European avian-like and classical swine H1N1 influenza A viruses. J Virol 2009, 83(11):5485-5494.
34. Beyer W.E., Palache A.M., Luchters G., Nauta J., Osterhaus A.D. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res 2004, 103(1-2):125-132.
35. Bizebard T., Gigant B., Rigolet P., Rasmussen B., Diat O., Bosecke P., et al. Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature 1995, 376(6535):92-94.
36. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16(3):265-273.
37. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324(5924):246-251.
38. Vareckova E., Mucha V., Wharton S.A., Kostolansky F. Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies. Arch Virol 2003, 148(3):469-486.
39. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010;6(2):e1000796.
40. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011;208(1):181-93.
41. Pica N., Hai R., Krammer F., Wang T.T., Maamary J., Eggink D., et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci USA 2012, 109(7):2573-2578.
42. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Investig 2010, 120(5):1663-1673.
43. Hofshagen M., Gjerset B., Er C., Tarpai A., Brun E., Dannevig B., et al. Pandemic influenza A(H1N1)v: human to pig transmission in Norway?. Eur Surveill 2009, 14(45).
44. Weingartl H.M., Berhane Y., Hisanaga T., Neufeld J., Kehler H., Emburry-Hyatt C., et al. Genetic and pathobiologic characterization of pandemic H1N1 2009 influenza viruses from a naturally infected swine herd. J Virol 2010, 84(5):2245-2256.
45. Ferrari M., Borghetti P., Foni E., Robotti C., Di Lecce R., Corradi A., et al. Pathogenesis and subsequent cross-protection of influenza virus infection in pigs sustained by an H1N2 strain. Zoonoses Public Health 2010, 57(4):273-280.
46. van Riel D., den Bakker M.A., Leijten L.M., Chutinimitkul S., Munster V.J., de Wit E., et al. Seasonal and pandemic human influenza viruses attach better to human upper respiratory tract epithelium than avian influenza viruses. Am J Pathol 2010, 176(4):1614-1618.
47. Ladekjaer-Mikkelsen A.S., Nielsen J., Stadejek T., Storgaard T., Krakowka S., Ellis J., et al. Reproduction of postweaning multisystemic wasting syndrome (PMWS) in immunostimulated and non-immunostimulated 3-week-old piglets experimentally infected with porcine circovirus type 2 (PCV2). Vet Microbiol 2002, 89(2-3):97-114.
48. Roos A.K., Eriksson F., Walters D.C., Pisa P., King A.D. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther: J Am Soc Gene Ther 2009, 17(9):1637-1642.
49. Nielsen J., Vincent I.E., Botner A., Ladekaer-Mikkelsen A.S., Allan G., Summerfield A., et al. Association of lymphopenia with porcine circovirus type 2 induced postweaning multisystemic wasting syndrome (PMWS). Vet Immunol Immunopathol 2003, 92(3-4):97-111.
50. Summerfield A., McNeilly F., Walker I., Allan G., Knoetig S.M., McCullough K.C. Depletion of CD4(+) and CD8(high+) T-cells before the onset of viraemia during classical swine fever. Vet Immunol Immunopathol 2001, 78(1):3-19.